NASDAQ$CRDF
Cardiff Oncology Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Cardiff Oncology reported its financial results for the first quarter of 2025, showing a net loss of $13.434 million and a decrease in cash and cash equivalents.
Cardiff Oncology, Inc. reported a net loss of $13.434 million for the first quarter of 2025, compared to a net loss of $10.011 million for the same period in 2024. Total revenues decreased to $0.109 million from $0.205 million year-over-year. The company's cash and cash equivalents stood at $24.095 million as of March 31, 2025, down from $51.470 million at the end of 2024. Operating expenses increased significantly, driven by higher research and development costs.
- Net loss for Q1 2025 was $13.434 million, an increase from $10.011 million in Q1 2024.
- Total revenues decreased to $0.109 million in Q1 2025 from $0.205 million in Q1 2024, primarily from royalties.
- Cash and cash equivalents decreased to $24.095 million as of March 31, 2025, from $51.470 million at December 31, 2024.
- Operating expenses rose to $14.491 million in Q1 2025 from $11.138 million in Q1 2024, mainly due to increased research and development costs.
Headline financials
Revenue & EPS history
Cardiff Oncology · Revenue · Quarterly
$109K
Revenue by segment
Cardiff Oncology · $41K total across 1 segment · Q1 2026
- Royalties$41K—100.0%
Forward guidance
Cardiff Oncology expects to continue incurring losses and requiring additional capital to advance its clinical trial programs. The company believes its current cash resources are sufficient to fund operations into the first quarter of 2027.
Tailwinds
- Sufficient cash to meet funding requirements for at least the next 12 months following the issuance date of the financial statements.
- Projected cash runway extends into the first quarter of 2027.
- Ongoing clinical trials for onvansertib in multiple indications, including RAS-mutated mCRC, mPDAC, SCLC, and TNBC.
- FDA agreement for a seamless Phase 3 trial with an interim ORR endpoint for accelerated approval.
- Positive preliminary efficacy data from TROV-054 Phase 1b/2 trial in KRAS-mutated mCRC, with an ORR of 29% across evaluable patients.
Headwinds
- Expectation to continue incurring net losses for the foreseeable future.
- Anticipated need for additional capital to further advance clinical trial programs and support other operations.
- Uncertainty regarding the availability of additional funding on acceptable terms or at all.
- Potential for additional dilution to stockholders if funds are raised by issuing equity securities.
- High risk of program completion due to uncertainties in drug development, long clinical testing durations, and stringent regulatory approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+2.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+3.0%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+118.2%
Q4 2010
Best reaction
-21.2%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | +3.6% | — | |
| Q4 2025 | +12.9% | +14.1% | -8.8% | |
| Q3 2025 | -3.1% | -0.4% | -6.2% | |
| Q2 2025 | -1.3% | -24.2% | -36.6% | |
| Q1 2025 | +4.0% | +2.5% | +37.4% | |
| Q4 2024 | +4.4% | +5.2% | -19.0% | |
| Q3 2024 | -19.2% | -17.6% | -39.4% | |
| Q2 2024 | +11.2% | +5.1% | -1.4% | |
| Q1 2024 | -16.8% | -21.7% | -24.8% | |
| Q4 2023 | +59.9% | +100.5% | +193.4% | |
| Q3 2023 | +5.7% | +3.8% | +20.0% | |
| Q2 2023 | -5.0% | -8.3% | -15.6% | |
| Q1 2023 | +1.1% | -4.8% | -12.4% | |
| Q4 2022 | +2.3% | +7.6% | -4.1% | |
| Q3 2022 | -4.7% | -10.7% | +5.4% | |
| Q2 2022 | +15.0% | +30.0% | +27.7% | |
| Q1 2022 | -7.7% | -11.9% | -0.7% | |
| Q4 2021 | +7.1% | +0.4% | -5.6% | |
| Q3 2021 | -5.1% | -3.6% | -14.1% | |
| Q2 2021 | +15.0% | +19.4% | +51.3% | |
| Q1 2021 | -5.5% | -13.1% | -24.5% | |
| Q4 2020 | +0.6% | +8.0% | -3.1% | |
| Q3 2020 | +10.6% | +5.8% | +26.6% | |
| Q2 2020 | -14.6% | -10.2% | -3.4% | |
| Q1 2020 | +0.8% | +6.7% | +167.5% | |
| Q4 2019 | -2.8% | +12.8% | -24.1% | |
| Q3 2019 | +1.8% | +2.4% | -20.8% | |
| Q2 2019 | -4.1% | -10.0% | +10.6% | |
| Q1 2019 | -8.1% | -11.2% | -11.2% | |
| Q4 2018 | +25.2% | +47.0% | +18.2% | |
| Q3 2018 | +6.7% | +4.0% | -6.7% | |
| Q2 2018 | -1.2% | -1.2% | +0.0% | |
| Q1 2018 | +0.0% | -3.6% | -47.3% | |
| Q4 2017 | -6.2% | -3.1% | +6.2% | |
| Q3 2017 | -1.5% | -4.4% | -26.5% | |
| Q2 2017 | -7.1% | +1.2% | -13.1% | |
| Q1 2017 | -5.0% | -1.2% | +1.3% | |
| Q4 2016 | -21.2% | -28.5% | -37.0% | |
| Q3 2016 | -5.6% | -15.5% | -29.6% | |
| Q2 2016 | -6.6% | -0.4% | -11.0% | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -18.7% | — | — | |
| Q3 2015 | +11.7% | — | — | |
| Q2 2015 | -15.0% | — | — | |
| Q1 2015 | +9.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q4 2013 | +7.9% | — | — | |
| Q3 2013 | +12.2% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q4 2012 | -2.4% | — | — | |
| Q1 2013 | -2.4% | — | — | |
| Q3 2012 | +2.3% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | +8.8% | — | — | |
| Q4 2011 | -3.9% | — | — | |
| Q3 2011 | -17.1% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +118.2% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +13.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro